{
    "nctId": "NCT01623349",
    "briefTitle": "Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer",
    "officialTitle": "Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Ovarian Cancer, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 118,
    "primaryOutcomeMeasure": "Determine MTD and RP2D of the Combination of BKM120 and Olaparib, and the Combination of BYL719 and Olaparib",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed recurrent high grade serous ovarian cancer or triple negative breast cancer\n* Subjects with recurrent, metastatic triple negative breast cancer must have had at least 1 chemotherapy regimen for metastatic breast cancer or have developed metastatic breast cancer within 1 year of completion of adjuvant chemotherapy\n* Prior therapy for high grade serous ovarian cancer subjects must have included a first-line platinum-based regimen\n* At least 4 weeks since prior radiation therapy, 3 weeks since prior chemotherapy and 6 weeks if the last regimen included BCNU or mitomycin C\n* At least 4 weeks since any small-molecular kinase inhibitors or any other type of investigational agent\n* Life expectancy of at least 4 months\n* Able to swallow and tolerate oral medications\n\nExclusion Criteria:\n\n* Evidence of bowel obstruction, abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of study entry\n* Current dependency on IV hydration or total parental nutrition\n* Diabetes mellitus unless well controlled\n* Pregnant or breast feeding\n* History of grade 3 or 4 toxicities with previous PI3kinase inhibitor or PARP inhibitor\n* Current or active dermatologic diagnoses that would preclude interpretation of skin toxicities of BKM120\n* Receiving any medications or substances that are strong inhibitors or inducers of CYP3A4\n* History of cardiac dysfunction or disease\n* Persistent toxicities (greater than or equal to CTCAE grade 2) caused by previous cancer therapy\n* Major surgery within 14 days of starting study treatment\n* Evidence of coagulopathy or bleeding diathesis\n* History of major depressive episode, bipolar disorder, obsessive/compulsive disorder, schizophrenia, history of suicide attempt or ideation or homicide/homicidal ideation\n* CTCAE grade 3 or greater anxiety\n* Uncontrolled, intercurrent illness\n* Known HIV positive and on combination antiretroviral therapy\n* Receiving chronic treatment with steroids or another immunosuppressive agent",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}